Medication-related osteonecrosis of the jaw remains a debilitating challenge for dental specialists, oncologists, and endocrinologists worldwide. Clinicians often find conventional conservative interventions insufficient for refractory necrotic lesions. Consequently, therapeutic interest has increasingly centered on the off-label application of teriparatide for MRONJ. This synthetic parathyroid hormone fragment stimulates skeletal remodeling and promotes mucosal closure. Recent evidence offers renewed hope for patients suffering from non-healing exposed necrotic jawbone.

Evaluating Teriparatide for MRONJ in Clinical Practice

Managing necrotic bone exposure requires a delicate balance between halting disease progression and promoting tissue regeneration. Historically, antiresorptive therapies like bisphosphonates and denosumab suppress osteoclastic activity to prevent skeletal events in osteoporosis and metastatic malignancy. However, prolonged suppression impairs bone turnover in the maxillofacial skeleton, leading to poor socket healing and exposed necrotic lesions. When standard wound care fails, healthcare providers must seek reliable adjunctive therapies to salvage jaw continuity and restore mucosal integrity.

Therefore, researchers have actively investigated osteoanabolic agents to reverse local microvascular and bone turnover arrest. Teriparatide, a recombinant human parathyroid hormone analogue, provides an intermittent anabolic stimulus directly to osteoblasts. In contrast to antiresorptive medications, teriparatide accelerates both bone formation and bone resorption, facilitating rapid turnover of necrotic bone. Clinicians originally deployed this agent for severe systemic osteoporosis, yet clinical case series have repeatedly documented accelerated jawbone recovery. Moreover, patients receiving adjunctive osteoanabolic therapy frequently report faster relief from localized facial pain and purulent discharge. Consequently, multidisciplinary teams are reassessing clinical pathways to integrate anabolic bone agents into standard maxillofacial management strategies.

Key Systematic Review Findings on Parathyroid Hormone Therapy

A landmark systematic review and meta-analysis synthesized data from twenty-eight international studies comprising 278 patients with established jaw osteonecrosis. Notably, all included studies evaluated teriparatide, examining its role in disease management and symptom resolution across diverse cohorts. The researchers compared 161 patients treated with teriparatide against 117 patients who received conventional management without parathyroid hormone analogues.

The results demonstrated remarkable clinical outcomes in favor of the anabolic peptide. Specifically, MRONJ improvement occurred in 90.1% of patients receiving teriparatide compared to 81.2% in the non-teriparatide group. Furthermore, meta-analytic calculations revealed an impressive odds ratio of 5.81, confirming a substantial statistical advantage for the teriparatide cohort. Additionally, the investigators noted that patients achieved the highest overall resolution rates when clinicians combined parathyroid hormone therapy with both surgical debridement and non-surgical measures. However, the authors emphasized the need for cautious interpretation because many included publications featured small cohort sizes and variable assessment methodologies. Nonetheless, the synthesized evidence strongly confirms that teriparatide markedly accelerates resolution when incorporated into comprehensive multi-modal care pathways.

Mechanisms of Teriparatide in Craniofacial Bone Regeneration

The maxillofacial region possesses a uniquely dynamic bone turnover rate that depends heavily on balanced osteoblast and osteoclast communication. When antiresorptive agents accumulate within the alveolar ridge, they severely diminish physiological remodelling capacity. In addition, these drugs often compromise local soft tissue microvasculature, leading to impaired mucosal healing following dental extractions.

Fortunately, teriparatide counteracts these localized deficits through distinct physiological pathways. Intermittent administration of parathyroid hormone fragments induces cyclic adenosine monophosphate signalling in pre-osteoblasts, which stimulates osteoblast differentiation and survival. Furthermore, the peptide promotes the expression of vascular endothelial growth factor, enhancing regional angiogenesis and capillary ingrowth into ischemic bone beds. As a result, the surrounding periosteum regains vascular competence, which accelerates soft tissue epithelisation over previously exposed necrotic cortical bone. Concurrently, teriparatide restores bone remodeling units by stimulating alkaline phosphatase activity and osteocalcin production. Therefore, this biological mechanism not only promotes the spontaneous separation of avascular sequestra but also encourages robust new bone formation within underlying defects.

Synergistic Surgical and Non-Surgical Treatment Protocols

The systematic review highlighted that teriparatide achieves its greatest therapeutic impact when clinicians implement it alongside multi-modal interventions. Traditionally, clinicians debated whether surgical intervention worsened necrotic bone exposure or provided definitive debridement. Today, evidence suggests that combining targeted conservative surgery with osteoanabolic support yields superior outcomes.

Typically, non-surgical foundations require meticulous antimicrobial mouth rinses, targeted systemic antibiotics, and professional dental hygiene to control superficial bacterial biofilms. Once clinicians stabilise soft tissue inflammation, they can perform conservative surgical sequestrectomy or shallow debridement to remove non-viable cortical plates. Concurrently, administering daily subcutaneous teriparatide during the perioperative phase significantly stimulates healthy osteogenesis at the margins of the surgical bed. Moreover, this synergistic sequence accelerates secondary intention wound closure and prevents recurrent bone breakdown. Clinical teams must ensure adequate oral intake of calcium and vitamin D during treatment to support rapid bone mineralization. Consequently, combining pharmacological anabolism with surgical debridement transforms a historically refractory condition into a highly manageable clinical challenge.

Patient Selection and Clinical Safety Considerations

While teriparatide demonstrates compelling efficacy for refractory osteonecrosis, clinicians must carefully evaluate patient eligibility before initiating therapy. In particular, healthcare providers must distinguish patients with benign metabolic bone disorders from those undergoing oncology treatments. Most regulatory bodies approve teriparatide exclusively for severe postmenopausal or glucocorticoid-induced osteoporosis, meaning that jaw osteonecrosis remains an off-label indication.

Furthermore, clinicians must respect absolute and relative contraindications when prescribing parathyroid hormone analogues. Patients with skeletal malignancies, active bone metastases, prior radiation therapy to the craniofacial skeleton, or pre-existing hypercalcemia should not receive teriparatide due to safety concerns. Additionally, patients with Paget disease of bone or unexplained elevations of alkaline phosphatase require alternative management strategies. Conversely, patients who developed jaw necrosis secondary to oral bisphosphonates for osteoporosis represent ideal candidates for this anabolic therapy. Clinicians should monitor serum calcium, creatinine, and intact parathyroid hormone levels during baseline workup and subsequent follow-ups. Thus, strict diagnostic vigilance and appropriate patient selection protect patient safety while maximizing therapeutic efficacy.

Translating Evidence into Multidisciplinary Practice in India

In India, the escalating burden of osteoporosis and cancer-related bone metastases has caused a steady rise in antiresorptive prescriptions. Unfortunately, many patients undergo invasive dental extractions without prior dental clearance, placing them at heightened risk for jaw necrosis. Furthermore, awareness of osteonecrosis protocols varies widely across primary care and dental specialties.

Therefore, bridging the communication gap between oncologists, endocrinologists, and maxillofacial surgeons is essential for timely intervention. When Indian clinicians encounter stubborn unhealed sockets persisting past eight weeks, they should promptly consider specialist referral and multidisciplinary review. Indian tertiary centers have increasingly embraced daily subcutaneous teriparatide protocols for refractory cases, especially for non-cancer patients who failed conservative wound care. Moreover, generic teriparatide formulations and biosimilars available in India have significantly lowered medication costs, making this advanced osteoanabolic therapy far more accessible. Ultimately, integrating proactive dental screenings with accessible osteoanabolic therapies will substantially enhance patient outcomes and improve overall quality of life across Indian healthcare settings.

Frequently Asked Questions

Can cancer patients with bone metastases receive teriparatide for MRONJ?

Generally, clinicians avoid prescribing teriparatide to cancer patients who have active bone metastases or previous radiation therapy. Parathyroid hormone analogues carry theoretical risks of stimulating malignant skeletal cell proliferation. Therefore, oncologists and oral surgeons restrict teriparatide use primarily to patients who developed jaw osteonecrosis during antiresorptive treatment for benign osteoporosis. In rare, highly refractory oncologic situations, a multidisciplinary tumor board must thoroughly balance the clinical risks before considering off-label therapy.

What is the typical dosage and duration of teriparatide for MRONJ healing?

Most published clinical protocols administer daily subcutaneous injections of 20 micrograms of teriparatide for eight to twelve weeks. Some complex cases require extended treatment lasting up to six months until complete mucosal coverage occurs. Additionally, clinicians prescribe daily oral calcium and vitamin D supplements to support active bone mineralisation. Patients undergo regular radiographic imaging and clinical evaluations to assess bone regeneration, ensuring prompt cessation of the drug once complete healing takes place.

Is surgery still necessary when using teriparatide to treat jaw osteonecrosis?

Yes, surgical intervention remains an essential component for achieving optimal resolution in advanced jaw osteonecrosis. Meta-analytic findings indicate that combining conservative surgical debridement with teriparatide yields significantly higher healing rates than medical therapy alone. Surgery mechanically removes avascular cortical sequestra and bacterial biofilms that pharmaceuticals cannot eliminate. Consequently, teriparatide provides the anabolic biological stimulus that accelerates vascular ingrowth and epithelial wound closure once the surgeon successfully excises non-viable bone tissue.

Disclaimer: This content is for informational and educational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional regarding any medical conditions, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Alabdulaaly L et al. Parathyroid Hormone for Medication-Related Osteonecrosis of the Jaw: A Systematic Review and Meta-Analysis. Oral Dis. 2026 Nov 01. doi: 10.1111/odi.70551. PMID: 42967897.
2. Sim IW, Borromeo GL, Tsao C, et al. Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial. J Clin Oncol. 2020;38(26):2971-2980.
3. Ruggiero SL, Dodson TB, Aghaloo T, et al. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update. J Oral Maxillofac Surg. 2022;80(5):920-943.